U.S. Markets closed

Cytek Biosciences, Inc. (CTKB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W
23.65-1.07 (-4.33%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close24.72
Open24.63
Bid22.80 x 4000
Ask25.00 x 1100
Day's Range22.92 - 24.92
52 Week Range17.40 - 28.70
Volume204,573
Avg. Volume416,186
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.33
  • GlobeNewswire

    Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

    FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. Cytek’s management is scheduled to present on Tuesday, September 14th, at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors

  • GlobeNewswire

    Cytek Biosciences Reports Second Quarter 2021 Financial Results

    FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $30.4 million for the second quarter, representing a 59% increase over the second quarter of 2020Expanded the installed base to 855 instruments, with 104 instrument placements during the second quarterLaunched the Cytek Aurora Cell Sorter (CS), a high-dimensional benc

  • GlobeNewswire

    Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwriters of its previously announced initial public offering, which closed on July 27, 2021, have exercised in full their option to purchase 2,184,695 additional shares of common stock at the price to the public of $17.00 per share. With the addition of the full exercise of the underwriters’ option to p